EHA 2024: Updates in the Treatment of CLL - Episode 5

Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy

July 15, 2024

Catherine C. Coombs, MD, Matthew S. Davids, MD, MMSc, Richardo D. Parrondo, MD , Nicole Lamanna, MD, Alexey V. Danilov, MD, PhD

A chronic lymphocytic leukemia expert examines patient criteria for first-line doublet therapy (venetoclax plus BTK inhibitor) versus triplet therapy, while also addressing findings from the CAPTIVATE trial.

EP. 1: Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024

EP. 2: Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL

EP. 3: Frontline BTKi Selection

EP. 4: Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib

Now Viewing

EP. 5: Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy

EP. 6: Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL

EP. 7: EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches

EP. 8: Navigating Treatment Approaches for R/R CLL

EP. 9: How Experts View MAIC Data That was Presented at EHA 2024

EP. 10: BTKi Intolerance in Real-world Practice & Management Strategy

EP. 11: Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

EP. 12: Approach to Hypertension Management With BTKi Treatment

EP. 13: Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib

EP. 14: Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing

EP. 15: Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

EP. 16: TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices

EP. 17: EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

EP. 18: Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

EP. 19: Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

EP. 20: Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies

EP. 21: Clinical Pearls and Impacts to Practice from EHA 2024

In which patients may you consider 1L doublet therapy (VEN + BTKi) or triplet therapy? How do available data inform your treatment decision?